Hospital
Public Hospital District No 3 of Whitman County
Public Hospital District No 3 of Whitman County was paid $9.10M by Medicaid between Jan 2018 and Dec 2024, across 133 billing codes. Its largest line is 99283, emergency room visit (moderate) — 8.9% of everything it billed.
33Billing provider infoPUBLIC HOSPITAL DISTRICT NO 3 OF WHITMAN COUNTY
COLFAX, WA 99111
COLFAX, WA 99111
33aNPI1922009448assigned 08/09/2005
33bProvider typeCritical Access Hospital
28Total paid$9.10M
24GClaims177,373
24DCodes billed133
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#16 of 30
Median peer was paid$9.10M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,593 | $686K | |
| 2019 | 19,501 | $890K | |
| 2020 | 28,115 | $1.08M | |
| 2021 | 34,498 | $1.41M | |
| 2022 | 35,477 | $1.94M | |
| 2023 | 31,622 | $2.01M | |
| 2024incomplete | 17,567 | $1.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.9% | 4,044 | 3,207 | $805K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.6% | 22,701 | 16,459 | $784K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.7% | 5,286 | 1,814 | $605K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.4% | 2,390 | 1,863 | $587K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 2,556 | 2,204 | $447K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 1,266 | 969 | $447K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.6% | 13,380 | 8,462 | $423K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.5% | 1,969 | 1,474 | $409K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 463 | 421 | $379K |
| 80053 | Comprehensive metabolic panel | 3.9% | 12,819 | 10,527 | $359K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.6% | 2,003 | 1,315 | $332K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.2% | 13,702 | 10,982 | $291K |
121 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 2,194 | $290K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.7% | 2,086 | $244K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.3% | 1,571 | $208K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 2.2% | 2,156 | $196K |
| G0378 | Hospital observation service, per hour | 1.8% | 66 | $160K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 380 | $155K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 2,632 | $118K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 12,814 | $118K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 4,910 | $115K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 156 | $76K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,208 | $76K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 922 | $74K |
| 80061 | Lipid panel | <1% | 2,803 | $70K |
| 84484 | <1% | 2,019 | $69K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 328 | $67K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 609 | $66K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 956 | $62K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,254 | $62K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,638 | $61K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 871 | $52K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 423 | $50K |
| 82607 | <1% | 1,253 | $46K | |
| 83605 | <1% | 1,527 | $42K | |
| 81025 | <1% | 1,325 | $34K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,603 | $34K |
| 80050 | General health panel | <1% | 284 | $33K |
| 84439 | <1% | 1,268 | $32K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 225 | $32K |
| 86140 | <1% | 1,939 | $32K | |
| 81001 | <1% | 2,706 | $26K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,254 | $25K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $23K |
| 85651 | <1% | 1,854 | $22K | |
| 83880 | <1% | 787 | $21K | |
| 83690 | <1% | 957 | $19K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 791 | $19K |
| 84145 | <1% | 770 | $19K | |
| 99307 | <1% | 2,929 | $17K | |
| 81003 | <1% | 1,674 | $17K | |
| 83735 | <1% | 993 | $17K | |
| 97161 | <1% | 193 | $15K | |
| 82746 | <1% | 496 | $15K | |
| 87186 | <1% | 704 | $15K | |
| 97113 | <1% | 126 | $14K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 751 | $13K |
| 80305 | <1% | 798 | $13K | |
| 83540 | <1% | 662 | $12K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 168 | $12K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 223 | $11K |
| 81002 | <1% | 1,715 | $11K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 55 | $11K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $11K |
| 85610 | <1% | 1,072 | $10K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 242 | $8K |
| 82728 | <1% | 224 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 861 | $8K |
| 73030 | <1% | 78 | $7K | |
| 83550 | <1% | 356 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 254 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 797 | $6K |
| 87088 | <1% | 371 | $6K | |
| 96376 | <1% | 55 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 253 | $6K |
| 90686 | <1% | 249 | $5K | |
| 87400 | <1% | 75 | $5K | |
| 84153 | <1% | 129 | $4K | |
| 73630 | <1% | 38 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 169 | $3K |
| 82150 | <1% | 170 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,476 | $3K |
| 80306 | <1% | 51 | $3K | |
| 82962 | <1% | 280 | $3K | |
| 82553 | <1% | 145 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 179 | $3K |
| 82550 | <1% | 345 | $3K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 38 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 866 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,535 | $3K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 25 | $3K |
| 90688 | <1% | 96 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 162 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 222 | $2K |
| 72100 | <1% | 13 | $2K | |
| 73560 | <1% | 36 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 353 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 966 | $2K |
| 85379 | <1% | 26 | $2K | |
| 90837 | Psychotherapy session, about an hour | <1% | 16 | $2K |
| 87077 | <1% | 86 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 117 | $2K |
| 99335 | <1% | 44 | $2K | |
| 0124A | <1% | 36 | $1K | |
| 87040 | <1% | 30 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 19 | $1K |
| 84550 | <1% | 60 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 219 | $1K |
| 82570 | <1% | 64 | $1K | |
| 84481 | <1% | 45 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 510 | $1K |
| 87081 | <1% | 29 | $952.84 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 139 | $938.77 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 221 | $842.56 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 55 | $780.11 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 320 | $756.50 |
| 86803 | <1% | 12 | $640.79 | |
| 83874 | <1% | 22 | $557.92 | |
| 82043 | <1% | 50 | $525.84 | |
| 85730 | <1% | 14 | $518.77 | |
| 90662 | <1% | 91 | $419.62 | |
| 84702 | <1% | 14 | $413.54 | |
| 99334 | <1% | 13 | $159.04 | |
| A9270 | Non-covered item or service | <1% | 4,687 | $53.18 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 41 | $26.24 |
| G0008 | Administration of influenza virus vaccine | 0% | 227 | $0.00 |
| 91307 | 0% | 17 | $0.00 | |
| 80320 | 0% | 14 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 228 | $0.00 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 0% | 15 | $0.00 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 28 | $0.00 |
| 91312 | 0% | 34 | $0.00 | |
| 91300 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, ABBY (CFO)